Verapamil: what is the mechanism of its anticarcinogenic activity? by Brambilla, G.
Br. J. Cancer (1994), 69, 792 i) Macmillan Press Ltd., 1994
LETTER TO THE EDITOR
Verapamil: what is the mechanism of its anticarcinogenic activity?
Sir - In their paper on the inhibition by verapamil of hepato-
carcinogenesis induced by N-nitrosomorpholine in Sprague-
Dawley rats Uehara et al. (1993) provide two possible
explanations for the significant decreases in the number and
the volume of GST-positive and GGT-positive hepatic
lesions and in the incidence and the volume of hepatocellular
carcinomas observed in rats treated with this calcium channel
blocker: (i) the reduction of total caloric intake; (ii) the
verapamil-induced decrease in the hepatocyte cytosolic cal-
cium concentration and/or its activity as al-adrenergic recep-
tor antagonist. I agree that these two possibilities cannot be
discarded, but a third possibility should be considered: the
reversal by verapamil of the resistance induced by the car-
cinogen in preneoplastic hepatocytes. This possibility is based
on the resistant hepatocyte theory developed by Solt and
Farber (1976), who hypothesised that an early event in liver
carcinogenesis is the induction in a rare hepatocyte of resis-
tance to the cytotoxic and mitoinhibitory effect ofcarcinogens.
Subsequently the carcinogen creates a selective environment
that inhibits the proliferation of normal hepatocytes but not
of the resistant initiated ones. As a matter of fact induction
of resistant hepatocytes in vivo in the rat has been observed
with several carcinogens, including N-nitrosomorpholine
(Tsuda et al., 1980). More recently Burt and Thorgeirsson
(1988) showed that treatment with certain carcinogens in-
creases the rat liver RNA levels for two proteins involved in
cellular handling of hepatotoxins: (i) the multidrug trans-
porter P-glycoprotein, an energy-dependent efflux system for
cytotoxic drugs that is the product of the MDR-1 gene; and
(ii) cytochrome P450 isoform d, a component of the system
that oxidises harmful xenobiotics. The calcium channel
blocker verapamil belongs to the family of chemicals which
have been found to antagonise multidrug resistance in a
variety of cell lines and in in vivo tumour models when
co-administered with agents to which the cells are resistant,
and it has been clearly shown that it acts by inhibiting the
P-glycoprotein-associated, energy-dependent outward drug
transport (Ford & Hait, 1990). Therefore it is reasonable to
hypothesise that in the presence of verapamil initiated hepa-
tocytes lose at least in part the peculiar resistance to the
cytotoxic activity of the carcinogen that allows their selective
proliferation. Consequently the formation of preneoplastic
lesions and their progression to hepatocellular carcinomas is
hindered.
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